

Murray JJ, Mullins MD, Knapp H, Keeler SL, Serafin WE, Keane B, Roberts LJ II, Struthers BJ, Oates JA. Regulation of the immune response by eicosanoids: Pharmacology and clinical effects of prostaglandin E in aspirin-sensitive syndromes. *Am J Therapeut.* 2:739-748, 1995.

Kane G, Pollice M, Cohn J, Dworski R, Murray J, Sheller J, Kim C-J, Fish J, Peters S. Insights into mechanisms of IGE mediated human lung inflammation derived from segmental antigen challenge studies employing a 5-lipoxygenase inhibitor. *J Aller Clin Immunol.* 97:646-654, 1996.

Israel E, Cohn J, Dube L, Drazen JM and the Zileuton Clinical Trial Group. Effect of treatment with Zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. *JAMA.* 275:931-936, 1996.

Vitola JV, Holsinger JP, Atkinson JB, Forman MB, Murray JJ. Inhibition of neutrophil activation as a mechanism for the reduction of myocardial reperfusion injury by lidocaine in the rabbit model. *Am Heart J.* 133:315-322, 1997.

In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, Silverman ES, Collins T, Fischer AR, Keith TP, Serino K, Kim SW, DeSanctis GT, Yandava C, Pillari A, Rubin P, Kemp J, Israel E, Busse W, Ledford D, Murray JJ, Segal A, Tinkelman D, Drazen JM. Naturally occurring mutations in the 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. *J Clin Invest.* 99:1130-1137, 1997.

Busse WW, Casale TB, Murray JJ, Petrocella V, Cox F and K Rickard. Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma. *Am J Managed Care.* 4:1579-87, 1998.

Murray JJ, NL Church, WA Anderson, DI Bernstein, SE Wenzel, A Emmett and KA Rickard. Concurrent use of salmeterol with inhaled steroids is more effective than steroid-dose increases. *Allergy Asthma Proc.* 20:173-180, 1999.

Stein CM, JJ Murray and AJJ Wood. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporin effect. *Clin Chem.* 45:1477-84, 1999.

Dworski R, Murray JJ, Roberts LJ 2nd, Oates JA, Morrow JD, Fisher L, Sheller JR. Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. *Am J Respir Crit Care Med.* 160(6):1947-1951, 1999.

Hartert TV, Dworski RT, Mellen BG, Oates JA, Murray JJ, Sheller JR. Prostaglandin E2 decreases allergen-stimulated release of prostaglandin D2 in airways of subjects with asthma. *Prostaglandin E2 decreases allergen-stimulated release of prostaglandin D2 in airways of subjects with asthma.* *Am J Respir Crit Care Med.* 162(2 Pt 1):637-640, 2000.

Murray JJ, Solomon E, McCluskey D, Zhang J, Palmer R, Notario G. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. *Clin Ther.* 2000 Dec;22(12):1421-32.

Raddassi K, Murray JJ. Ethanol increases superoxide anion production stimulated with 4beta-phorbol 12-myristate 13-acetate in human polymorphonuclear leukocytes. Involvement of protein kinase C. *Eur J Biochem.* 267(3):720-727, 2000.

Dahlen B, Szczeklik A, Murray JJ; Celecoxib in Aspirin-Intolerant Asthma Study Group. Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group. *N Engl J Med.* 2001 Jan 11;344(2):142.

Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. *Allergy Asthma Proc.* 2002 Nov-Dec;23(6):391-8.

Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, Rickard KA. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. *Chest.* 120(2):423-430, 2001.

Sheller JR, Dworski R, Hagaman D, Oates J, Murray J. The prostaglandin E agonist, misoprostol, inhibits airway IL-5 production in atopic asthmatics. *Prostaglandins & Other Mediators.* 70:185-193, 2002.

Sheller JR, Dworski R, Hagaman D, Oates J, Murray J. The E prostaglandin agonist, misoprostol, inhibits airway IL-5 production in atopic asthmatics. *Intl Arch Aller Immunol.* 70(1-2):185-193, 2002.

Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. *Am J Med.* 115(7):587-589, 2003.

Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. *Am J Med.* 115(7):587-589, 2003.

Lumry W, Hampel F, LaForce C, Kiechel F, el-Akkad T, Murray JJ. A comparison of once-daily triamcinolone acetonide aqueous and twice-daily beclomethasone dipropionate aqueous nasal sprays in the treatment of seasonal allergic rhinitis. *Allergy Asthma Proc.* 24(3):203-210, 2003.

Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol.* 113(1):59-65, 2004.

Murray J, Rosenthal R, Somerville L, Blake K, House K, Baitinger L, VanderMeer A, Dorinsky P. Fluticasone propionate and salmeterol

administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. *Ann Allergy Asthma Immunol.* 2004 Oct;93(4):351-9.

Murray JJ, Emparanza P, Lesinskas E, Tawadrous M, Breen JD. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. *Otolaryngol Head Neck Surg.* 2005 Aug;133(2):194-200.

Murray JJ. Cardiovascular risks associated with beta-agonist therapy. *Chest.* 2005 Jun;127(6):2283-5.

Amrol DJ, Hagaman DD, Sheller JR, Murray JJ. Soluble CD23 and interleukin-1 receptor antagonist in human asthmatics following antigen challenge. *J Asthma.* 42(1):73-76, 2005.